Navigation Links
James F. Szigethy Named Curemark's Director of New Product Development
Date:9/7/2010

RYE, N.Y., Sept. 7 /PRNewswire/ -- Curemark (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that James F. Szigethy, formerly a consultant for Curemark, has assumed the position of Director of New Product Development.  In his new position, Szigethy will have direct oversight of improving existing products and directing the development of new products.  As Curemark continues to anticipate expansion of its clinical trials program, Szigethy will oversee and coordinate all activities across a variety of Curemark product programs, the company said.

Dr. Joan Fallon, Curemark's Founder and CEO said, "We are very excited  to have James assume this new position.  Curemark has a strong focus on innovation coupled with excellence and James' credentials as an experienced pharmacist and consultant are a tremendous asset to us."

"I am excited to have the opportunity to implement Curemark's strategic vision and this is a truly exciting company to work for," remarked Szigethy.  "Curemark is focused on children with conditions for whom either no treatment or inadequate treatment is available and I am proud to be at the forefront of the development of new products to further our studies and Curemark's mission."

Szigethy's new responsibilities will include formulation development, overseeing Curemark's product production and expansion of its product portfolio. He has been with the company since 2007.

Szigethy graduated from St. John's University in 1994 with a B.A. in Psychology. He attained his B.S. in Pharmacy in 2001 and became a supervising pharmacist for Wal-Mart, where his department was recognized as Wal-Mart's Northeast Region Pharmacy of the Year in 2006.

Curemark currently is conducting Phase III clinical trials for CM-AT, an autism treatment that will be one of the first to address the underlying physiology of autism.  CM-AT is based on Dr. Fallon's breakthrough research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein.  The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function.  The FDA has designated CM-AT as a Fast Track drug.

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thoratec Presentation at Raymond James Conference to Be Webcast
2. Hill-Rom Announces Appointment of James R. Giertz to Board of Directors
3. AMD LASERS Names Dr. James Jesse as Medical Director
4. Dr. James F. Pingpank to Present at Leading Regional Therapies Conference
5. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
6. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
7. Cape Medical Supply Named to Prestigious Inc. 5000 List of Americas Fastest Growing Private Companies for Fourth Year in a Row
8. SAM Medical Products Named to Inc. 5000 List of the Fastest-Growing Private Companies in America
9. MedNet Solutions Named to the Inc. 5000 List of Fastest Growing Companies for the Fourth Consecutive Year
10. BlueDot Medical, Inc. Named to 2010 Inc. 500/5000
11. KPaul Named to the Inc. 500 Fastest Growing Companies List for 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... May 4, 2017  Fortuna Fix Inc. (" Fortuna ... the first to eliminate the need for embryonic and fetal ... treat neurodegenerative diseases. Fortuna announced today ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald ... MPH; and Professor James Giordano , PhD. ...
(Date:5/4/2017)... 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... solutions, today announced that it is teaming up with ... Limited to lower diabetes healthcare costs in ... which is available throughout all provinces and territories in ... eligible for additional savings when shopping for Dario supplies ...
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
Breaking Medicine Technology:
(Date:5/21/2017)... ... May 20, 2017 , ... ... designs created specifically for use in Final Cut Pro X. The business-oriented elements ... productions. Pixel Film Studios’ ProParagraph Corporate will deliver a professional and distinguished look ...
(Date:5/21/2017)... ... ... Florida Pain Relief Group, a division of Physician Partners of America (PPOA), is ... Melbourne, on Monday, May 22. Initially the clinic will be supervised by Physician Partners ... 23 pain management clinics in Florida and the Dallas-Fort Worth, Texas metro area, and ...
(Date:5/21/2017)... Houston,Texas (PRWEB) , ... May 21, 2017 , ... ... but if it's been longer than six months since you've seen a dentist, ... dentist twice per year and getting x-rays once per year. , Dental checkups ...
(Date:5/19/2017)... ... May 19, 2017 , ... ... in an upcoming episode of Innovations with Ed Begley, Jr., airing fourth quarter ... the distributor of a clean, organic dietary supplement made from naturally occurring ingredients. ...
(Date:5/19/2017)... CA (PRWEB) , ... May 19, 2017 , ... The ... consulting to families and entrepreneurs throughout the California Central Valley, is announcing a joint ... of raising community support for a local kid’s camp event. , The Boys and ...
Breaking Medicine News(10 mins):